Ono Pharmaceutical Co., Ltd.
4528
Classifica tra le azioni
#2567
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged... Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
Prezzo delle azioni
$15.91
Capitalizzazione di mercato
$7.48B
Variazione (1 giorno)
0.99%
Variazione (1 anno)
34.71%
Paese
JP
Scambia Ono Pharmaceutical Co., Ltd. (4528)
Categoria
Healthcare
Storico dividendi per Ono Pharmaceutical Co., Ltd. (4528)
Ono Pharmaceutical Co., Ltd. (simbolo azionario: 4528) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Ono Pharmaceutical Co., Ltd. (4528) dal 2026 al 2026
Pagamenti annuali dei dividendi
| Anno | Dividendo (rettificato per split azionari) | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Elenco di tutti i pagamenti di dividendi
| Anno | Dividendo | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Dividendi di aziende simili o concorrenti
| Azienda | Numero di pagamenti di dividendi | Il paese |
|---|---|---|
| 215.00% |
US
|
|
| 225.00% |
US
|
|
| 53.00% |
US
|
|
| 223.00% |
US
|
|
| 33.00% |
CH
|
